Abdulla A. Damluji, MD, PhD Profile picture
May 11 21 tweets 7 min read Twitter logo Read on Twitter
Hierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease: @JACCJournals @NailaIjaz_MD

This analysis evaluated the timing of developing cognitive impairment & frailty in pts at risk for CAD!!

Summary 👇👇 Image
1/ In this @JACCJournals study, we examined the patterns of frailty and cognitive impairment (CI) development and their associations with cardiovascular outcomes in older adults without prior known coronary artery disease (CAD) during a 5-year follow-up. 🧠❤️

#NHATS
2/ We found that the highest proportion of participants (37.8%) developed cognitive frailty first, followed by those who developed a combination of physical and cognitive frailty (8.9%), and then those who developed only physical frailty (7.0%). 📈🚶‍♂️

#aging
3/ Participants who developed both CI and frailty simultaneously were older and had a higher prevalence of multiple chronic conditions and baseline disability compared to the other groups. 👵🏽🩺

#GeriatricSyndromes
4/ Compared to participants who developed frailty or CI first, those who developed simultaneous CI and frailty had a higher risk of developing major adverse cardiac events (MACEs) at 5-year follow-up, mostly attributed to mortality. ⚠️💔 #CardiovascularRisk Image
5/ The study confirms that CI, both with frailty and independent of frailty, was associated with a higher incidence of adverse cardiac events and mortality than those without CI.
🧠🚑 #CognitiveImpairment Image
6/ CI can cause difficulties in managing cardiovascular risk factors, poor dietary habits, and overall worse physical health, leading to an increased likelihood for adverse cardiovascular outcomes and mortality.

🏥 #compliance
7/ The study suggests that integrating screening tools for geriatric conditions in cardiovascular practice could identify patients who may benefit from interventions that address geriatric risks and modify the approach for cardiovascular therapies. 📋👩‍⚕️ #prevention
8/ Gaps in knowledge: Effective interventions to prevent and reverse geriatric risks in context of cardiovascular illness.

Geriatric conditions may be EMM in the association between therapeutics and CV outcomes.
Few more additional info for those interested:

9/ 🎯 Study aims: To evaluate incidence of CI & frailty, examine patterns & assess their influence on MACE 📚💡
10/

🔬 We Analyzed the 2011 NHATS baseline cohort data

📚 NHATS: Prospective study focusing on older patients' functioning 🧓🚶‍♀️
11/📋🎯 Study population:

Age ≥ 65, no history of CAD before 2011 NHATS baseline visit 📏

💡 Exposure categories:

1) Intact
2) Frail first
3) CI first
4) Frail-CI 📋
12/ 🔄 We evaluated the temporal association between physical frailty, cognitive function & incident CVD in NHATS study ⏳🔁
13/ 🔍 Definitions 📚

🤲 Physical frailty: vulnerability to stressors, decline in reserve & function across multiple systems 📉

🧠 CI: cognitive vulnerability, higher risk of developing dementia 🌪️🚩
14/ 🎯 Study outcomes:

1️⃣ Time to first incident MACE (death, AMI, coronary heart disease, stroke, peripheral vascular disease) ⏰💔
2️⃣ Assessing geriatric risks: functioning, ADL, IADL, disability, mobility disability 🧓🏃‍♂️
15/📈 RESULTS 📉

👥 2,189 NHATS participants:

1,011 (46%): Intact (no frailty or CI)
154 (7%): Frailty-first
829 (38%): CI-first
195 (9%): Frailty-CI co-occurrence

📋 Baseline data:

Mean age: 77.5 years
61%: ≥75 years old
62%: Female
Majority: White/Caucasian
16/ 📊 Frailty-CI group (highest risk):

Older, more females, ethnic minorities
More help in self-care, mobility, household activities
Higher rate of disability
17/ 📉 5-year follow-up:

25% died
59% had MACE (30% CAD)
Frail-CI: highest all-cause mortality (60%), MACE (87%)
Frail-CI: highest PVD (40%), CAD (40%)
Frail-first: highest AMI (11%), stroke (29%)
18/ 🔍

Adjusted analysis:

Frailty, CI or both associated with greater risk of MACE, death
Frail-CI: higher risk of AMI
Frail-first: higher risk of stroke
CI-first & frail-CI: no longer associated with stroke risk ImageImage
19/ Of course many thanks to my friends and co-investigators for their help in making this work more mature: @RaniKHasan @DrAROrkaby @Ajar_Kochar @MichaelGNanna; and the great @JeremyWalstonMD (others not on twitter)

Full manuscript on @JACCJournals 👇👇

authors.elsevier.com/sd/article/S27…
20/ What is next?

A new SOA by this research team led by @NailaIjaz_MD expanding on our understanding of cognitive frailty in the context of CVD.

Dr Ijaz is a🌟

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

May 10
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association: @CircAHA

Nice statement on high risk group

Summary 👇👇👇 Image
1/ 🌏 Asian Americans (AsA) are the fastest growing ethnic group in the US 🇺🇸. They face high risks of Type 2 diabetes (T2D) & atherosclerotic cardiovascular disease (ASCVD) - major risks.
2/ 📊 Yet, most studies lump all AsA subgroups in one category, potentially hiding disparities in T2D & ASCVD prevalence.
Read 42 tweets
Apr 26
Thread #2:

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: @JACCJournals

* Easier to digest in small snippets, but not sure how to do this best, but let's experiment.

...continued starting from 13 through 18 Image
13/ Understanding HFpEF Diagnostic Challenges

❓Establishing a diagnosis of HFpEF may be difficult given the lack of obvious structural abnormalities and normal natriuretic peptide levels, especially in obese individuals.
14/ Clinical Scoring Systems for HFpEF Diagnosis

💡Clinical scoring systems such as H2FPEF and HFA-PEFF can help in the diagnostic evaluation of HFpEF.
Read 8 tweets
Apr 26
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee: @JACCJournals

Dense document, but will try to break it down w threads

Starting here👇👇👇 Image
1/The symptoms and signs of heart failure (HF) are best summarized by the Framingham HF Diagnostic Criteria.
2/ To make a diagnosis, 2 major criteria or 1 major criterion plus 2 minor criteria are required.
Read 14 tweets
Apr 24
Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels: PICCOLETO-II 3-Year Follow-Up: @JACCJournals

The promise of drug coated balloons for small vessels (2 to 2.75mm)!

Summary 👇👇👇 Image
1/ 🚀PICCOLETO II is an open label, multi center, European clinical trial comparing novel paclitaxel drug coated balloons DCB to new-generation DES
2/ 📊 The use of DCB in small coronary vessels showed reduced MACEs & vessel thrombosis at 3 years vs modern DES. Image
Read 8 tweets
Apr 4
Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification: @CircAHA

Mechanistic study: Toll-Like Receptor 3 = TLR3

Here is few point summary

👇👇👇 Image
1/ 🧪 This study identifies TLR3 as a key element in aortic valve calcification. BGN, a central component of the extra cellular matrix (ECM), induces the TLR3 signaling cascade, resulting in valvular interstitial cells (VICs) transforming into bone-forming osteoblast-like cells.
2/ 🔍 The study reveals the first direct interaction between BGN and TLR3 in the cell type primarily responsible for aortic valve calcification. This suggests that BGN may govern TLR3-dependent levels of basal type I interferons (IFN) in human fibroblasts.
Read 8 tweets
Apr 3
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study: @CircAHA

5-point summary below: 👇👇 Image
(1/5)

🚫 This trial is a single-arm, open label, phase IV clinical study that evaluated coronary atherosclerotic plaque regression with a PCSK9 inhibitor in asymptomatic patients with familial hypercholesterolemia (FH)
(2/5)

💊 The study tested alirocumab (PRALUENT) at 150 mg every 14 days for 78 weeks + high-intensity statin therapy, and assessed plaque burden by noninvasive coronary CTA imaging in both men and women.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(